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Received July 4, 2011; accepted November 4, 2011AbstractBackground: TRIM29 belongs to the tripartite motif (TRIM) protein family. It has been reported to be up-regulated or be down-regulated in
many cancer types, suggesting the oncogenic function of TRIM29 may be depend on different molecular signaling pathway. It was found that
b-catenin function (a key molecule in the Wnt signaling pathway) was required for TRIM29’s oncogenic effects. TRIM29 gene expression was
also found to be heterogeneous in non-small-cell lung cancer (NSCLC) subtypes. In this study, the possible associations of TRIM29 expression
with clinicopathological factors, prognosis, and b-catenin in human NSCLC were analyzed.
Methods: TRIM29 and b-catenin expression of tumor and adjacent normal tissues in 251 cases of NSCLC treated by surgery was detected by the
Immunohistochemical method. The relationship between clinical pathological data, b-catenin, and TRIM29 expression was analyzed.
Results: TRIM29 expression of tumor tissues was significantly higher than adjacent normal tissues. Expression of TRIM29 in squamous cell
carcinoma (SC) tissues was positively correlated with abnormal expression of b-catenin, histological grade, tumor-node-metastasis (TNM) stage,
and lymph node metastasis and that was positively correlated with tumor size, histological grading, TNM stage and lymph node metastasis in
adenocarcinoma (AC). TRIM29 expression in SC and AC was significantly different and the intensity of poorly differentiated SC was
significantly higher than that of AC. High-expression of TRIM29, poorly differentiated grade, and high clinical stage were independent
prognostic indicators.
Conclusion: We considered that TRIM29 may play a reference role in distinguish poorly differentiated AC and SC of NSCLC, combining with
CK5/6 and CK7, and it could improve postoperative assessment and have the reference value for clinical treatment. The interaction between
TRIM29 and b-catenin may participate in the development of lung SC.
Copyright  2012 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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Lung cancer is the leading cause of cancer-related death in
the United States, only 15% of all lung cancer patients live 5
years or more after diagnosis.1 Rapidly metastasis and spread
are important reasons for the low 5-year survival rate of lung
cancer. The prediction of clinical prognosis still depends on
conventional pathologic variables such as tumor size, tumor
grade, lymph node, and clinical stage. It is of great clinical* Corresponding author. Dr. Guo-Yi Yang. Department of Pathology, Wuxi
People’s Hospital Affiliated to Nanjing Medical University, Wuxi 214023,
China.
E-mail address: zzywin2006@yahoo.com.cn (G.-Y. Yang).
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doi:10.1016/j.jcma.2012.04.015value to find sensitive and specific early biomarkers for the
diagnosis and prognosis of this malignancy, as well as novel
therapeutic strategies. Non-small-cell lung cancer (NSCLC),
the predominant form of lung cancer, formerly viewed as
a frequent unique disease of uniform presentation, is now
viewed as a mosaic of diseases defined by pathological char-
acteristics or molecular characteristics. It consists of two
major histological subtypes: squamous cell carcinoma (SC)
and adenocarcinoma (AC). The subclasses differ in their
clinical biological behavior, with AC tending to worse
outcomes than SC.2 Currently, histological type has been an
important factor in selecting treatment among NSCLC,
because novel molecularly targeted therapies have shown
different activities in histological subclasses.3 Therefore, thehinese Medical Association. All rights reserved.
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ological diagnosis of NSCLC. Recently, TRIM29 gene
expression was found to be heterogeneous in NSCLC subtypes
according to gene-expression profiles.4 Initially known as the
ataxia telangiectasia group D complementing gene (ATDC),
TRIM29 was cloned from ataxia telangiectasia group D
fibroblasts as a gene with the ability to complement sensitivity
to ionizing radiation. 5
TRIM29, located at chromosome 11q23, is expressed nor-
mally in placenta, lung, thymus, prostate, testis, and colon,while
it was undetectable in heart, brain, skeletal muscle, pancreas,
spleen, ovary, or small intestine.6 It belongs to the tripartite
motif (TRIM) protein family. This family consists of at least 37
member proteins and is characterized by its unique structure:
three zinc-binding domains (RING, B-box type 1, and B-box
type 2), followed by a coiled-coil region. While some of the
domainsmay be absent or present (TRIM29 contains theB1-B2-
CC domains but lacks the R domain),7 TRIM family has been
implicated in a variety of cellular processes, such as develop-
ment and growth. TRIM29 has been reported to be up-regulated
in a number of cancer types and to also be down-regulated in
some other cancer types suggesting the function of TRIM29
may be depend on different cellular context and molecular
signaling pathway.8 Wang8 found that TRIM29 expression
correlated with elevated b-catenin levels in pancreatic cancer,
and b-catenin function (a key molecule in Wnt signaling
pathway) was required for TRIM29’s oncogenic effects.
However, both TRIM29 and b-catenin gene expression in
NSCLC have not been reported.
In this study, we explored TRIM29 and b-catenin gene
expression in human NSCLC. The possible associations of
TRIM29 gene expression with clinicopathological factors,
prognosis, and b-catenin were also analyzed.
2. Methods2.1. PatientsRetrospective analysis was performed on NSCLC patients
who had undergone surgery between January 2007 and
December 2009 in our department of Wuxi People’s Hospital
Affiliated to NanjingMedical University. Themedian age of the
patients was 62 years, ranging from 33e84 years. There were
188 males and 63 females (2.98:1). According to World Health
Organization (WHO) standards, there were 127 cases of SC and
124 cases of AC, well-differentiated¼ 24, differentiated¼ 118,
and poorly differentiated ¼ 109. According to tumor-node-
metastasis (TNM) stage (the 7th edition of TNM staging of the
Union for International Cancer Control and American Joint
Committee on Cancer in 2009), there were 140 (55.8%) in
staging level Ⅰ-Ⅱ and 111 (44.2%) in staging levelⅢ-Ⅳ. A total
of 131 (52.2%) patients were positive for lymph node metas-
tasis, while 120 (47.8%) were negative. No adjuvant radio-
therapy or chemotherapy was administered before surgery. One
representative block was selected for immunohistochemical
study. The study was permitted by the patients or the family
members of patients.2.2. ImmunohistochemistryParaffin slices were treated according to the EnVision
immunohistochemical kit (Maxim Biotechnology Ltd, Fuzhou,
China), and results were analyzed using a double-blind
method. Five high-power fields (400) were selected at
random, and two pathologists evaluated scores independently.
Phosphate buffered saline (PBS), instead of the primary anti-
body, was used as negative control. cytokeratin (CK)7 (OV-TL
12/30 þ 72.2, Labvision, Labvision Co, Kalamazoo, USA) and
CK5/6(D5/16B4, Labvision, USA) expression were detected,
CK5/6 marked for SC, and CK7 marked for AC. TRIM29
(polyclonal antibodies, Lifespan Inc, Seattle, WA, USA)
expression was scored according to the intensity of the dye
color and the number of positive cells. The intensity of the dye
color was graded as 0 (no color), 1 (light yellow), 2 (light
brown), or 3 (brown), and the number of positive cells was
graded as 0 (<5%), 1 (5%e25%), 2 (25%e50%), 3 (51%e
75%), or 4 (>75%). The two grades were added together and
specimens were assigned to one of 4 levels: 0-1 score
(e, negative), 2 scores (þ, weakly positive), 3-4 scores (þþ,
positive), and more than 5 scores (þþþ, strongly positive).2.3. Evaluation of staining of b-catenin (CAT-5H10,
Labvision)For counting cells with nuclear and/or cytoplasm staining,
three microscopic fields with 200-fold magnification were
randomly chosen. Evaluation of staining was carried out based
on whether nuclear and/or cytoplasmic staining is detectable.
Under microscopic field of 200-fold magnification, tissues are
positive for b-catenin abnormal expression, if more than 10%
of cells show cytoplasmic and/or nuclear staining.2.4. Statistical analysisAll data were analyzed using SPSS 11.5 (SPSS Inc, IL, USA).
c2 tests (or Fisher’s exact test) were used for samples classified as
percentages; Spearman analysis was used to determine the
correlationbetween twovariables.Both theKaplan-Meiermethod
and log-rank test were used for single variant analysis, and a Cox
model was used to analyze relationships between survival rates
and multiple variables. A p value < 0.05 were considered to be
significant.
3. Results3.1. Association between TRIM29 and b-catenin
expression and clinicopathological factors in lung SCAmong 127 cases of lung SC, weakly positive, positive and
strongly positive were 11 (8.7%), 55 (43.3%) and 61(48.0%)
cases respectively (Fig. 1), and there was no negative case. Only
17 cases (13.4%) were weakly positive in adjacent normal lung
tissue (10 cm distant from cancer), the rest belonging to
negative. TRIM29 expression of tumor tissue was significantly
higher ( p < 0.05). Furthermore, TRIM29 expression was
Fig. 1. Strong staining of TRIM29 in lung poorly differentiated SC.
SC ¼ squamous cell carcinoma.
Fig. 3. b-catenin cytoplasm and nuclear staining poorly differentiated SC.
SC ¼ squamous cell carcinoma.
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histologic grade (Figs. 2 and 3), TNM stage and lymph node
metastasis, while not correlated with sex, age, and tumor size
(Table 1).3.2. Association between TRIM29 and b-catenin
expression and clinicopathological factors in lung ACAmong 124 cases of lung AC, negative, weakly positive
and positive were 25 (22.2%), 84 (67.7%) and 15 (12.1%)
cases respectively (Fig. 4), and there was no strong positive
case. In the adjacent normal lung tissue only 11(8.9%)
cases were weak positive, the rest being negative. TRIM29
expression in lung AC tumor tissue was also significantly
increased ( p < 0.05). Simultaneously, TRIM29 expression
was positively correlated with tumor size, histologic grade,
TNM stage, and lymph node metastasis, and not correlated
with sex, age and abnormal expression of b-catenin
(Table 2).Fig. 2. b-catenin membrane staining in well-differentiated lung SC.
SC ¼ squamous cell carcinoma.3.3. Difference of TRIM29 expression in lung SC and ACIn Table 3, we found that TRIM29 expression in lung SC
and AC was significantly different. Tables 1 and 2 showed that
TRIM29 expression of SC was significantly higher in poorly
differentiated tumor, with strongly positive (62.0%) or positive
(35.2%), while AC was significantly weaker, with the majority
being weakly positive (74.4%) and no strong positive.3.4. Association between TRIM29 expression and
prognosis in lung SC patientsIn view of the closely correlation between TRIM29 and lung
SC, we conducted TRIM29 survival analysis on 56 cases of
lung SC with follow-up data. The 1-year and 3-year survival
rates of 56 cases were 84.2% and 53.4%, respectively. The
survival rate was significantly lower in the higher TRIM29
expression group ( p< 0 .01). These results are shown in Fig. 5.
By log-rank test, higher expression of TRIM29, higher histo-
logic grade, and TNM stage, and lymph node metastasis showedFig. 4. Light staining of TRIM29 in lung poorly differentiated AC.
AC ¼ adenocarcinoma.
Table 3
Difference of TRIM29 expression in lung SC and AC.
TRIM29 expression intensity p value
- þ þþ þþþ
Lung AC 25 84 15 0 <0.001
Lung SC 0 11 55 61
AC ¼ adenocarcinoma; SC ¼ squamous cell carcinoma.
Table 1
Correlation of TRIM29 expression and clinicopathological factors and b-cat-
enin expression in lung SC.
TRIM29 expression intensity p value
- þ þþ þþþ
b-catenin abnormal
expression
Negative 0 7 17 14 0.030
Positive 0 4 38 47
Age, y <60 0 0 4 5 0.499
60 0 11 51 56
Sex Male 0 7 47 58 0.772
Female 0 4 8 3
Tumor size 5 cm 0 8 36 36 0.330
>5 cm 0 3 19 25
Clinical stage IeII 0 10 42 24 <0.001
IIIeIV 0 1 13 37
Pathological grade I 0 3 2 0 <0.001
II 0 6 28 17
III 0 2 25 44
Lymph node metastasis Positive 0 10 41 13 <0.001
Negative 0 1 14 47
SC ¼ squamous cell carcinoma.
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no prognostic significance. Univariate analysis showed that the
following factors were significantly related to postoperative
survival: high TRIM29 expression, histologic grade and TNM
clinical stage ( p < 0 .05). These results are shown in Table 4.4. Discussion
TRIM29 encodes a 588 amino acid protein with multiple
zinc-finger motifs and an adjacent leucine-zipper motif and
thus may act as a transcriptional regulatory factor.9 TRIM29
has been reported to be overexpressed in bladder,10 colo-
rectal,11 ovarian,12 and endometrial cancers13 and in multiple
myeloma,14 with apparent reduced expression in breast,15 and
prostate cancers,16 suggesting that the function of TRIM29
may be dependent on different cellular context and molecular
signaling pathway. Using immunohistochemical analysis, weTable 2
Correlation of TRIM29 expression and clinicopathological factors and b-cat-
enin expression in lung AC.
TRIM29 expression intensity p value
- þ þþ þþþ
b-catenin abnormal
expression
Negative 9 22 1 0 0.051
Positive 16 62 14 0
Age, y <60 1 7 2 0 0.295
60 24 77 13 0
Sex Male 16 45 15 0 0.594
Female 9 39 0 0
Tumor size 5 cm 24 68 10 0 0.016
>5 cm 1 16 5 0
Clinical stage IeII 22 40 2 0 <0.001
IIIeIV 3 44 13 0
Pathological grade I 10 9 0 0 <0.001
II 13 46 7 0
III 2 29 8 0
Lymph node metastasis Positive 3 49 15 0 <0.001
Negative 22 35 0 0
AC ¼ adenocarcinoma.found TRIM29 protein was up-regulated in NSCLC than
adjacent normal tissues and correlated with clinicopatholog-
ical factors and prognosis, therefore speculating TRIM29 gene
over-expression may be involved in the pathogenesis of
NSCLC. Also, we found that TRIM29 over-expression and
abnormal expression of b-catenin was significantly correlated
in SC, but not in AC. Currently, many literatures had reported
that the abnormal expression of b-catenin play an important
role in the pathogenesis of NSCLC,17 but the correlation
between TRIM29 and b-catenin gene has not yet been repor-
ted. Wang8 found that TRIM29 as a protein highly expressed
in the majority of human pancreatic adenocarcinomas. Addi-
tionally, elevated levels of TRIM29 expression correlated with
elevated b-catenin levels in pancreatic cancer cell lines and
primary pancreatic cancers, and silencing of TRIM29 via
shRNA approaches antagonized b-catenin/T cell factor (TCF)-
mediated reporter activation and activation of TCF target
genes. Gene b-catenin was implicated in the oncogenic effects
of TRIM29 in vitro and in vivo, and the ability of TRIM29 to
increase b-catenin levels appeared to be attributable to
TRIM29’s effects on disheveled-2 protein expression.
TRIM29 is an important positive regulator of b-catenin-
dependent signaling in pancreatic cancer. Our results indicated
that lung SC (not lung AC) and pancreatic AC might exist
similar molecular signal pathogenesis involving relationship
between TRIM29 and b-catenin. The molecular mechanisms
need further study.
By real-time reverse transcriptase-polymerase chain reac-
tion, Kosaka and colleagues7 analyzed TRIM29 mRNA
expression status with respect to various clinicopathological
parameters in 124 patients with gastric cancer. Results indi-
cated that the expression of TRIM29 was far higher in gastric
cancer tumor tissue than in surrounding tissue. IncreasedFig. 5. TRIM29 survival analysis on 56 cases of lung SC. SC ¼ squamous cell
carcinoma.
Table 4
Multiple factor cox model regression variable form of lung SC.
B SE Wald df Sig. Exp(B) 95.0% CI for Exp(B)
Lower Upper
TRIM29 Expression Intensity 1.668 0.697 5.727 1 0.017 5.300 1.352 20.774
Clinical stage 2.079 0.667 9.707 1 0.002 7.993 2.162 29.553
Pathologic grade 1.325 0.583 5.159 1 0.023 3.760 1.199 11.793
B ¼ partial regression coefficient; CI ¼ confidence interval; df ¼ degree of freedome; Exp(B) ¼ hazard ratio; SC ¼ squamous cell carcinoma; SE ¼ standard error;
Sig. ¼ significance.
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associated with such parameters as histological grade, large
tumor size, and extent of tumor invasion, and it was an
independent predictor for lymph node metastasis. In the
TRIM29 high-expression group, furthermore, patients with
high TRIM29 mRNA expression showed a far poorer survival
rate. In pancreatic cancer cells, expression of TRIM29
promoted cellular proliferation and enhanced tumor growth
and metastasis.8 To investigate the biological role of TRIM29
expression in NSCLC, using immunohistochemistry (IHC), we
found that TRIM29 expression was positively correlated with
histologic grade, TNM stage, and lymph node metastasis in
lung SC and was positively correlated with tumor size,
histologic grade, TNM stage, and lymph node metastasis in
lung AC. Univariate analysis showed that the following factors
were significantly related to postoperative survival in lung SC:
TRIM29 high expression, histologic grade and TNM clinical
stage. Our results strongly suggest TRIM29 could be a valu-
able biomarker for the prediction of NSCLC prognosis.
Lymph node metastasis is usually a reliable prognostic indi-
cator, but it did not enter the multi-factor Cox model in this
study, although the log-rank test suggested its positive
significance. We analysis that skip metastases and micro-
metastases, easily leading to missed diagnosis in routine
pathology work, might affect the statistical results in addition
to the limited number of follow-up cases. Tumor stage is the
prognostic factor; however, it is relatively hysteretic for
prognosis. So, high expression of TRIM29 (particularly strong
positive of lung SC and positive of AC) could lead to clinical
attention in spite of no lymph node metastasis. Currently,
further studies are needed on molecular mechanism of
TRIM29 promoting invasion and metastasis and investigations
of whether TRIM29 could be used as a target for novel ther-
apeutic approaches in NSCLC.
NSCLC includes two major histological subtypes: SC and
AC. Traditionally, histological classification of NSCLC is
carried out by the standard histochemical staining using
hematoxylin and eosin. However, it is difficult to see the
typical histological structures in poorly differentiated tumor.
Moreover, the increased use of limited bronchoscopic or
needle biopsies available for diagnosis increase the difficulty
of histological type and there is a relatively high rate of
morphological misdiagnosis in needle biopsy samples
compared to surgical specimens.18 Immunohistochemistry
could improve pathological diagnosis with a combination of
AC markers (CK7) and SC markers (p63 and CK5/6).
However, the specificity of each marker for one particularhistological subtype remains low.19 We found that there was
significant difference of TRIM29 expression between lung SC
and AC. Particularly in poorly differentiated tumor, TRIM29
expression of SC was significantly higher, with strongly
positive (62.0%) and positive (35.2%), while AC was signifi-
cantly weaker, with the majority being weakly positive
(74.4%) and no strong positive. Therefore, we considered that
TRIM29 may play a reference role in distinguish poorly
differentiated AC and SC of NSCLC, combining with CK5/6
and CK7.
In conclusion, by immunohistochemistry, this study indi-
cated that TRIM29 and b-catenin (a key molecule of Wnt
signaling pathway) interactions may play an important role in
the pathogenesis of lung SC, and TRIM29 biomarker has the
application value in the pathological diagnosis and clinical
pathology of NSCLC. We recommend that routine patholog-
ical diagnosis of lung cancer could combine the immune
markers TRIM29, improving the accuracy of pathological
diagnosis and having guiding values for clinical staging,
treatment and survival assessment.References
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